Last reviewed · How we verify

Voglibose + Metformin — Competitive Intelligence Brief

Voglibose + Metformin (Voglibose + Metformin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: α-glucosidase inhibitor + biguanide combination. Area: Diabetes.

phase 3 α-glucosidase inhibitor + biguanide combination α-glucosidase enzymes; AMPK pathway / mitochondrial complex I Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Voglibose + Metformin (Voglibose + Metformin) — University of Zambia. Voglibose inhibits intestinal α-glucosidases to slow glucose absorption, while metformin reduces hepatic glucose production and improves insulin sensitivity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Voglibose + Metformin TARGET Voglibose + Metformin University of Zambia phase 3 α-glucosidase inhibitor + biguanide combination α-glucosidase enzymes; AMPK pathway / mitochondrial complex I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (α-glucosidase inhibitor + biguanide combination class)

  1. University of Zambia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Voglibose + Metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/voglibose-metformin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: